181
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin

, , , , , , , , , & show all
Pages 2260-2262 | Received 21 Mar 2022, Accepted 30 Apr 2022, Published online: 20 May 2022
 

Disclosure statement

F.S. reports research funding from Roche Sequencing Solutions. All other authors do not report any conflicts of interest.

Additional information

Funding

This work was supported by Comprehensive Cancer Center Freiburg, by the Else Kröner-Fresenius-Stiftung (2018_A38, to F.S.), the Deutsche Forschungsgemeinschaft (SCHE 1870/3-1, to F.S.), the Fördergesellschaft Forschung Tumorbiologie (to F.S.), the Deutsche Gesellschaft für Innere Medizin (to F.S.), and the Biothera-Stiftung (to F.S.).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.